Nothing Special   »   [go: up one dir, main page]

SG10201903658QA - Personalized anti-cancer agent screening system - Google Patents

Personalized anti-cancer agent screening system

Info

Publication number
SG10201903658QA
SG10201903658QA SG10201903658QA SG10201903658QA SG10201903658QA SG 10201903658Q A SG10201903658Q A SG 10201903658QA SG 10201903658Q A SG10201903658Q A SG 10201903658QA SG 10201903658Q A SG10201903658Q A SG 10201903658QA SG 10201903658Q A SG10201903658Q A SG 10201903658QA
Authority
SG
Singapore
Prior art keywords
cancer agent
cancer
screening system
personalized
agent screening
Prior art date
Application number
SG10201903658QA
Inventor
Do Hyun Nam
Kyeung Min Joo
Original Assignee
Samsung Life Public Welfare Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Life Public Welfare Foundation filed Critical Samsung Life Public Welfare Foundation
Publication of SG10201903658QA publication Critical patent/SG10201903658QA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)

Abstract

PERSONALIZED ANTI-CANCER AGENT SCREENING SYSTEM The present invention relates to a personalized anti-cancer agent screening system, to a method for screening a personalized anti-cancer agent using said personalized anti-cancer agent screening system, and to a personalized anti-cancer agent screening apparatus. The personalized anti-cancer agent screening system of the present invention may not only select, from among a variety of candidate anti-cancer agents, the anti-cancer agent which exhibits optimum anti-cancer activity against a target patient- derived cancer cell but also may check in advance the treatment response which may be obtained when the selected anti-cancer agent is administered into the body of the patient. Thus, the personalized anti-cancer agent screening system of the present invention may not only reduce the trial and error and risk accompanied by a cancer treatment but also reduce the cost and time required for the treatment. FIG. -29-
SG10201903658QA 2012-12-11 2013-12-11 Personalized anti-cancer agent screening system SG10201903658QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20120143573A KR101327533B1 (en) 2012-12-11 2012-12-11 Novel screening system for personalized anti-cancer agents

Publications (1)

Publication Number Publication Date
SG10201903658QA true SG10201903658QA (en) 2019-05-30

Family

ID=49857311

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201504628UA SG11201504628UA (en) 2012-12-11 2013-12-11 Personalized anti-cancer agent screening system
SG10201903658QA SG10201903658QA (en) 2012-12-11 2013-12-11 Personalized anti-cancer agent screening system

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201504628UA SG11201504628UA (en) 2012-12-11 2013-12-11 Personalized anti-cancer agent screening system

Country Status (9)

Country Link
US (3) US20160103119A1 (en)
EP (1) EP2933636B1 (en)
JP (3) JP2016501027A (en)
KR (1) KR101327533B1 (en)
CN (1) CN104919315B (en)
ES (1) ES2886512T3 (en)
SA (1) SA113350064B1 (en)
SG (2) SG11201504628UA (en)
WO (1) WO2014092457A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101782005B1 (en) * 2015-05-28 2017-09-27 한국과학기술원 Cancer micro-environment array platform
KR102557289B1 (en) * 2016-01-27 2023-07-20 연세대학교 산학협력단 A patient-derived xenograft model of diffuse type of cancer and a method of producing thereof
KR101983547B1 (en) * 2016-04-04 2019-05-29 주식회사 싸이토젠 Personalized anticancer chemotherapy screening system and process using a short-term culture circulating tumor cell(ctc)
KR101895207B1 (en) * 2016-05-12 2018-09-07 주식회사 싸이토젠 The personalized anti-cancer agent screening system using the tumor cells derived on body fluid of patients with cancer
KR101993892B1 (en) 2016-06-03 2019-06-28 사회복지법인 삼성생명공익재단 Method of Screening Antibody Using Patient Derived Cell
IT201700004017A1 (en) * 2017-01-16 2018-07-16 React4Life Srl Bioreactor and method of use of said bioreactor
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
EP3775170A4 (en) * 2018-04-13 2022-01-26 Shanghai Lide Biotech Co., Ltd. Method for obtaining an animal model from conditionally reprogrammed cells and use of the animal model for screening anti-tumor drugs
CN108624561B (en) * 2018-05-26 2021-09-17 复旦大学 Primary tumor cell culture medium, culture method and application
CN115862890B (en) * 2022-08-31 2023-08-11 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) Anticancer drug screening method and system

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424209A (en) * 1993-03-19 1995-06-13 Kearney; George P. Automated cell culture and testing system
US9342657B2 (en) 2003-03-24 2016-05-17 Nien-Chih Wei Methods for predicting an individual's clinical treatment outcome from sampling a group of patient's biological profiles
WO2005014856A1 (en) * 2003-08-08 2005-02-17 Canbas Co., Ltd. Sensitivity test to predict efficacy of anti-cancer therapies
KR100689107B1 (en) * 2004-05-25 2007-03-09 가톨릭대학교 산학협력단 Method of determination of anticancer activity using multicellular layer in conjunction with cytotoxicity assay
JP2006166799A (en) * 2004-12-16 2006-06-29 Motoko Iijima Method for selecting and inspecting anticancer agent
EP2004695A2 (en) * 2005-07-08 2008-12-24 Xencor, Inc. Optimized anti-ep-cam antibodies
US20070071762A1 (en) 2005-09-21 2007-03-29 Ccc Diagnostics, Llc Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac)
CN101313221A (en) * 2005-09-21 2008-11-26 Ccc诊断有限责任公司 Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy(pac)
EP1792978A1 (en) * 2005-12-01 2007-06-06 Stiftung Caesar Center of Advanced European Studies and Research Means and methods for the isolation and characterization of cancer stem cells
US20080113390A1 (en) 2006-08-08 2008-05-15 In Suk Han Personalized assay for the identification of an effective therapy for cancer
GB2467691A (en) 2008-09-05 2010-08-11 Aueon Inc Methods for stratifying and annotating cancer drug treatment options
KR101046883B1 (en) * 2008-11-19 2011-07-06 재단법인 아산사회복지재단 How to collectively determine sensitivity to anticancer drugs
SG176571A1 (en) 2009-05-19 2012-01-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
JP2011115106A (en) * 2009-12-04 2011-06-16 Rei Medical Co Ltd Cancer cell aggregate and method for preparing the same
JP5809782B2 (en) * 2009-12-24 2015-11-11 株式会社ルネッサンス・エナジー・インベストメント Method for evaluating drug or radiosensitivity of cancer tissue-derived cell mass or cancer cell aggregate
CN103250176A (en) * 2010-08-13 2013-08-14 智能医学公司 System and method for producing personalized, customized pharmaceutical products
KR101371697B1 (en) 2011-02-07 2014-03-07 연세대학교 원주산학협력단 Patient-Tailored Cancer Chemotherapy
NZ615738A (en) * 2011-04-04 2015-11-27 Nestec Sa Methods for predicting and improving the survival of gastric cancer patients
US20140047570A1 (en) * 2011-04-19 2014-02-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Animal model of human cancer and methods of use

Also Published As

Publication number Publication date
US20230213501A1 (en) 2023-07-06
ES2886512T3 (en) 2021-12-20
WO2014092457A1 (en) 2014-06-19
EP2933636A4 (en) 2017-03-22
EP2933636A1 (en) 2015-10-21
EP2933636B1 (en) 2021-07-07
JP2017195887A (en) 2017-11-02
US20160103119A1 (en) 2016-04-14
SG11201504628UA (en) 2015-07-30
SA113350064B1 (en) 2016-04-05
JP2016501027A (en) 2016-01-18
CN104919315B (en) 2017-08-15
JP6867431B2 (en) 2021-04-28
US20200110071A1 (en) 2020-04-09
CN104919315A (en) 2015-09-16
KR101327533B1 (en) 2013-11-08
JP2019150043A (en) 2019-09-12

Similar Documents

Publication Publication Date Title
SG10201903658QA (en) Personalized anti-cancer agent screening system
IL279330A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
IL276434A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
PH12014501844B1 (en) Peptidomimetic macrocycles
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2021010672A (en) Diagnosis and therapy of cancer involving cancer stem cells.
TN2015000050A1 (en) Methods of treating a tauopathy
EP2739337A4 (en) Assemblies, systems, and methods for infusing therapeutic agents into the body
WO2014167126A3 (en) Platform for targeted delivery to stem cells and tumor cells and uses thereof
MX2024008825A (en) Composition for controlled ovarian stimulation.
AR092899A1 (en) USE OF MASITINIB FOR THE TREATMENT OF CANCER IN SUB-POPULATIONS OF IDENTIFIED PATIENTS USING PREDICTION FACTORS
EA201890598A3 (en) ANTIANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATION RESISTANT CANCER OF THE PROSTATE
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
EP2859898A4 (en) Therapeutic agent, treatment method and test method for diseases associated with activation of neutrophils
MX362111B (en) A method of improving liver function.
SG10201908587PA (en) Treatment regimens
WO2014005153A3 (en) Methods for treating mds1-evi1 mediated cancer
SG11201808253YA (en) Marker for predicting treatment response to anti-cancer agent in solid cancer patients
PH12014502464A1 (en) Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
UA79303U (en) use of taurine as agent for stabilizing the concentration in blood plasma in the treatment of fungal diseases
MX2018003308A (en) Localized delivery of anti-fugetactic agent for treatment of cancer.
WO2012139021A3 (en) TARGETING HK alpha FOR CONTROLLING BLOOD PRESSURE AND REGULATING ELECTROLYTE BALANCE
LV14615A (en) A remedy for lowering blood carbonyl-protein level
WO2013053034A3 (en) Thiazacridines used in anti-cancer therapy